Company’s 36-month beta value is 1.75.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 5 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for BCRX is 197.24M, and currently, short sellers hold a 10.03% ratio of that floaft. The average trading volume of BCRX on April 02, 2025 was 3.25M shares.
BCRX) stock’s latest price update
Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) has experienced a decline in its stock price by -3.33 compared to its previous closing price of 7.50. However, the company has seen a fall of -10.16% in its stock price over the last five trading days. globenewswire.com reported 2025-03-06 that RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted seven newly-hired employees restricted stock units (RSUs) covering an aggregate of 65,900 shares of BioCryst common stock. The RSUs were granted as of March 3, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
BCRX’s Market Performance
BCRX’s stock has fallen by -10.16% in the past week, with a monthly drop of -15.11% and a quarterly drop of -5.97%. The volatility ratio for the week is 3.14% while the volatility levels for the last 30 days are 4.11% for Biocryst Pharmaceuticals Inc The simple moving average for the last 20 days is -6.15% for BCRX’s stock, with a simple moving average of -5.33% for the last 200 days.
Analysts’ Opinion of BCRX
Many brokerage firms have already submitted their reports for BCRX stocks, with Wedbush repeating the rating for BCRX by listing it as a “Outperform.” The predicted price for BCRX in the upcoming period, according to Wedbush is $15 based on the research report published on February 25, 2025 of the current year 2025.
JP Morgan, on the other hand, stated in their research note that they expect to see BCRX reach a price target of $10. The rating they have provided for BCRX stocks is “Overweight” according to the report published on November 20th, 2023.
RBC Capital Mkts gave a rating of “Outperform” to BCRX, setting the target price at $10 in the report published on September 18th of the previous year.
BCRX Trading at -10.95% from the 50-Day Moving Average
After a stumble in the market that brought BCRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.68% of loss for the given period.
Volatility was left at 4.11%, however, over the last 30 days, the volatility rate increased by 3.14%, as shares sank -12.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -2.68% lower at present.
During the last 5 trading sessions, BCRX fell by -10.16%, which changed the moving average for the period of 200-days by +15.08% in comparison to the 20-day moving average, which settled at $7.73. In addition, Biocryst Pharmaceuticals Inc saw -3.59% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCRX starting from Hutson Nancy J, who sale 7,000 shares at the price of $7.54 back on Dec 13 ’24. After this action, Hutson Nancy J now owns 86,638 shares of Biocryst Pharmaceuticals Inc, valued at $52,780 using the latest closing price.
Hutson Nancy J, the Director of Biocryst Pharmaceuticals Inc, proposed sale 7,000 shares at $7.51 during a trade that took place back on Dec 13 ’24, which means that Hutson Nancy J is holding shares at $52,584 based on the most recent closing price.
Stock Fundamentals for BCRX
Current profitability levels for the company are sitting at:
- -0.01 for the present operating margin
- 0.97 for the gross margin
The net margin for Biocryst Pharmaceuticals Inc stands at -0.2. The total capital return value is set at -0.01.
Based on Biocryst Pharmaceuticals Inc (BCRX), the company’s capital structure generated 2.43 points at debt to capital in total, while cash flow to debt ratio is standing at -0.06. The debt to equity ratio resting at -1.7. The interest coverage ratio of the stock is -0.02.
Currently, EBITDA for the company is 12.81 million with net debt to EBITDA at 75.39. When we switch over and look at the enterprise to sales, we see a ratio of 4.92. The receivables turnover for the company is 5.7for trailing twelve months and the total asset turnover is 0.92. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.63.
Conclusion
In a nutshell, Biocryst Pharmaceuticals Inc (BCRX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
